•Executive Summary o Market Overview •Market Landscape o Market ecosystem o Value chain analysis •Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 •Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition •Market Segmentation by Product o Market segments o Comparison by Product o Hormone-based therapy - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Product •Customer landscape o Overview •Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o South America - Market size and forecast 2019-2024 o MEA - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography •Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher-priced units o Market challenges o Market trends •Vendor Landscape o Overview o Landscape disruption o Vendor Analysis •Vendors covered o Market positioning of vendors o AbbVie Inc. o Allergan Plc o Bayer AG o Ferring Pharmaceuticals AS o GlaxoSmithKline Plc o Merck & Co., Inc. o Merck KGaA o Novartis AG o Pfizer Inc. o Sanofi •Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations •1.Key Finding 1 •2.Key Finding 2 •3.Key Finding 3 •4.Key Finding 5 •5.Key Finding 6 •6.Key Finding 7 •7.Key Finding 8 •8.Market in focus •10.Parent market •13.Market characteristics •15.Offerings of vendors included in the market definition •17.Market segments •22.Global - Market size and forecast 2019 - 2024 ($ million) •23.Global market: Year-over-year growth 2019 - 2024 (%) •24.Five forces analysis 2019 & 2024 •27.Bargaining power of buyers •29.Bargaining power of suppliers •30.Threat of new entrants •31.Threat of substitutes •32.Threat of rivalry •34.Market condition - Five forces 2019 •36.Product placement - Market share 2019-2024 (%) •37.Comparison by Product •40.Hormone-based therapy - Market size and forecast 2019-2024 ($ million) •41.Hormone-based therapy - Year-over-year growth 2019-2024 (%) •44.Others - Market size and forecast 2019-2024 ($ million) •45.Others - Year-over-year growth 2019-2024 (%) •47. Market opportunity by Product •48.Customer landscape •50.Market share by geography 2019-2024 (%) •51.Geographic comparison •54.North America - Market size and forecast 2019-2024 ($ million) •56.North America - Year-over-year growth 2019-2024 (%) •59.Europe - Market size and forecast 2019-2024 ($ million) •61.Europe - Year-over-year growth 2019-2024 (%) •64.APAC - Market size and forecast 2019-2024 ($ million) •66.APAC - Year-over-year growth 2019-2024 (%) •69.South America - Market size and forecast 2019-2024 ($ million) •71.South America - Year-over-year growth 2019-2024 (%) •74.MEA - Market size and forecast 2019-2024 ($ million) •76.MEA - Year-over-year growth 2019-2024 (%) •78.Key leading countries •80.Market opportunity by geography ($ million) •81.Impact of drivers and challenges •82.Vendor landscape •84.Landscape disruption •86.Industry risks •88.Vendors covered •90.Market positioning of vendors •92.AbbVie Inc. - Overview •93.AbbVie Inc. - Business segments •94.AbbVie Inc. - Key offerings •95.AbbVie Inc. - Key customers •96.AbbVie Inc. - Segment focus •98.Allergan Plc - Overview •99.Allergan Plc - Business segments •100.Allergan Plc - Key offerings •101.Allergan Plc - Key customers •102.Allergan Plc - Segment focus •104.Bayer AG - Overview •105.Bayer AG - Business segments •106.Bayer AG - Key offerings •107.Bayer AG - Key customers •108.Bayer AG - Segment focus •110.Ferring Pharmaceuticals AS - Overview •111.Ferring Pharmaceuticals AS - Product and service •112.Ferring Pharmaceuticals AS - Key offerings •113.Ferring Pharmaceuticals AS - Key customers •114.Ferring Pharmaceuticals AS - Segment focus •116.GlaxoSmithKline Plc - Overview •117.GlaxoSmithKline Plc - Business segments •118.GlaxoSmithKline Plc - Key offerings •119.GlaxoSmithKline Plc - Key customers •120.GlaxoSmithKline Plc - Segment focus •122.Merck & Co. Inc. - Overview •123.Merck & Co. Inc. - Business segments •124.Merck & Co. Inc. - Key offerings •125.Merck & Co. Inc. - Key customers •126.Merck & Co. Inc. - Segment focus •128.Merck KGaA - Overview •129.Merck KGaA - Business segments •130.Merck KGaA - Key offerings •131.Merck KGaA - Key customers •132.Merck KGaA - Segment focus •134.Novartis AG - Overview •135.Novartis AG - Business segments •136.Novartis AG - Key offerings •137.Novartis AG - Key customers •138.Novartis AG - Segment focus •140.Pfizer Inc. - Overview •141.Pfizer Inc. - Business segments •142.Pfizer Inc. - Key offerings •143.Pfizer Inc. - Key customers •144.Pfizer Inc. - Segment focus •146.Sanofi - Overview •147.Sanofi - Business segments •148.Sanofi - Key offerings •149.Sanofi - Key customers •150.Sanofi - Segment focus •152.Currency conversion rates for US$ •153.Research Methodology •154.Validation techniques employed for market sizing •155.Information sources •156.List of abbreviations

AbbVie Inc., Allergan Plc, Bayer AG, Ferring Pharmaceuticals AS, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi